ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

REVATIO
Pulmonary hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

REVATIO Rx

Generic Name and Formulations:
Sildenafil 20mg; tabs.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for REVATIO:

Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening.

Limitations Of use:

No beneficial effect on exercise capacity in adding sildenafil to bosentan therapy.

Adult:

5mg or 20mg three times daily; separate dosing by 4–6hrs (see Interactions).

Children:

Not recommended.

Contraindications:

Concomitant organic nitrates, riociguat.

Warnings/Precautions:

Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia. Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP<90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions:

See Contraindications. Hypotension with nitrates. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Potentiated by inhibitors of CY3A4 or CYP2C9. Antagonized by CYP3A4 inducers. Concomitant α-blockers (eg, doxazosin) or amlodipine may cause symptomatic hypotension (monitor BP). Potentiates bleeding risk with Vit. K antagonists. Concomitant Viagra or other PDE5 inhibitors: not recommended.

See Also:

REVATIO INJECTION

REVATIO ORAL SUSPENSION

Pharmacological Class:

Phosphodiesterase type 5 inhibitor (cGMP-specific).

Adverse Reactions:

Epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea worsened, rhinitis, sinusitis, myalgia, pyrexia, paresthesia; hypotension, vision or hearing loss, priapism, vaso-occlusive crisis.

Metabolism:

Hepatic (CYP3A, CYP2C9).

Elimination:

Fecal (primary), renal.

Generic Availability:

Tabs (YES); Susp, inj (NO)

How Supplied:

Tabs—90; Susp—112mL (w. bottle adapter, oral syringe); Single-use vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs